329 related articles for article (PubMed ID: 27638202)
1. Leveraging premalignant biology for immune-based cancer prevention.
Spira A; Disis ML; Schiller JT; Vilar E; Rebbeck TR; Bejar R; Ideker T; Arts J; Yurgelun MB; Mesirov JP; Rao A; Garber J; Jaffee EM; Lippman SM
Proc Natl Acad Sci U S A; 2016 Sep; 113(39):10750-8. PubMed ID: 27638202
[TBL] [Abstract][Full Text] [Related]
2. Precancer Atlas to Drive Precision Prevention Trials.
Spira A; Yurgelun MB; Alexandrov L; Rao A; Bejar R; Polyak K; Giannakis M; Shilatifard A; Finn OJ; Dhodapkar M; Kay NE; Braggio E; Vilar E; Mazzilli SA; Rebbeck TR; Garber JE; Velculescu VE; Disis ML; Wallace DC; Lippman SM
Cancer Res; 2017 Apr; 77(7):1510-1541. PubMed ID: 28373404
[TBL] [Abstract][Full Text] [Related]
3. Transforming Cancer Prevention through Precision Medicine and Immune-oncology.
Kensler TW; Spira A; Garber JE; Szabo E; Lee JJ; Dong Z; Dannenberg AJ; Hait WN; Blackburn E; Davidson NE; Foti M; Lippman SM
Cancer Prev Res (Phila); 2016 Jan; 9(1):2-10. PubMed ID: 26744449
[TBL] [Abstract][Full Text] [Related]
4. The Immune Contexture Associates with the Genomic Landscape in Lung Adenomatous Premalignancy.
Krysan K; Tran LM; Grimes BS; Fishbein GA; Seki A; Gardner BK; Walser TC; Salehi-Rad R; Yanagawa J; Lee JM; Sharma S; Aberle DR; Spira AE; Elashoff DA; Wallace WD; Fishbein MC; Dubinett SM
Cancer Res; 2019 Oct; 79(19):5022-5033. PubMed ID: 31142513
[TBL] [Abstract][Full Text] [Related]
5. The Case for a Pre-Cancer Genome Atlas (PCGA).
Campbell JD; Mazzilli SA; Reid ME; Dhillon SS; Platero S; Beane J; Spira AE
Cancer Prev Res (Phila); 2016 Feb; 9(2):119-24. PubMed ID: 26839336
[TBL] [Abstract][Full Text] [Related]
6. Vaccines for Non-Viral Cancer Prevention.
Bayó C; Jung G; Español-Rego M; Balaguer F; Benitez-Ribas D
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681560
[TBL] [Abstract][Full Text] [Related]
7. From Premalignant Biology to Precision Interception: Connecting the Dots with a Curated Collection of Invited Articles.
Colbert Maresso K; Maitra A; Hawk ET; Vilar E
Cancer Prev Res (Phila); 2023 Jul; 16(7):365-367. PubMed ID: 37403656
[TBL] [Abstract][Full Text] [Related]
8. Cancer Immunoprevention: Current Status and Future Directions.
Keshavarz-Fathi M; Rezaei N
Arch Immunol Ther Exp (Warsz); 2021 Feb; 69(1):3. PubMed ID: 33638703
[TBL] [Abstract][Full Text] [Related]
9. Genetic driver events in premalignancy: LOH validated for marking the risk of oral cancer.
Cavenee WK
Cancer Prev Res (Phila); 2012 Sep; 5(9):1073-4. PubMed ID: 22911109
[TBL] [Abstract][Full Text] [Related]
10. Immune Profiling of Premalignant Lesions in Patients With Lynch Syndrome.
Chang K; Taggart MW; Reyes-Uribe L; Borras E; Riquelme E; Barnett RM; Leoni G; San Lucas FA; Catanese MT; Mori F; Diodoro MG; You YN; Hawk ET; Roszik J; Scheet P; Kopetz S; Nicosia A; Scarselli E; Lynch PM; McAllister F; Vilar E
JAMA Oncol; 2018 Aug; 4(8):1085-1092. PubMed ID: 29710228
[TBL] [Abstract][Full Text] [Related]
11. Classification, morphology and molecular pathology of premalignant lesions of the pancreas.
Cooper CL; O'Toole SA; Kench JG
Pathology; 2013 Apr; 45(3):286-304. PubMed ID: 23442735
[TBL] [Abstract][Full Text] [Related]
12. Advances and challenges in cancer immunoprevention and immune interception.
Stanton SE; Castle PE; Finn OJ; Sei S; Emens LA
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38519057
[TBL] [Abstract][Full Text] [Related]
13. From MGUS to Multiple Myeloma, a Paradigm for Clonal Evolution of Premalignant Cells.
van Nieuwenhuijzen N; Spaan I; Raymakers R; Peperzak V
Cancer Res; 2018 May; 78(10):2449-2456. PubMed ID: 29703720
[TBL] [Abstract][Full Text] [Related]
14. Prevention and treatment of urothelial premalignant and malignant lesions.
Wijkström H; Cohen SM; Gardiner RA; Kakizoe T; Schoenberg M; Steineck G; Tobisu K
Scand J Urol Nephrol Suppl; 2000; (205):116-35. PubMed ID: 11144892
[TBL] [Abstract][Full Text] [Related]
15. Early Events in the Molecular Pathogenesis of Lung Cancer.
Kadara H; Scheet P; Wistuba II; Spira AE
Cancer Prev Res (Phila); 2016 Jul; 9(7):518-27. PubMed ID: 27006378
[TBL] [Abstract][Full Text] [Related]
16. Hydrogel-Embedded Precision-Cut Lung Slices Model Lung Cancer Premalignancy Ex Vivo.
Blomberg R; Sompel K; Hauer C; Smith AJ; Peña B; Driscoll J; Hume PS; Merrick DT; Tennis MA; Magin CM
Adv Healthc Mater; 2024 Feb; 13(4):e2302246. PubMed ID: 37953708
[TBL] [Abstract][Full Text] [Related]
17. Premalignant and in situ breast disease: biology and clinical implications.
Arpino G; Laucirica R; Elledge RM
Ann Intern Med; 2005 Sep; 143(6):446-57. PubMed ID: 16172443
[TBL] [Abstract][Full Text] [Related]
18. Premalignancy of the testis and paratestis.
Emerson RE; Cheng L
Pathology; 2013 Apr; 45(3):264-72. PubMed ID: 23478232
[TBL] [Abstract][Full Text] [Related]
19. Cancer stem cell immunology and immunotherapy: Harnessing the immune system against cancer's source.
Ruiu R; Tarone L; Rolih V; Barutello G; Bolli E; Riccardo F; Cavallo F; Conti L
Prog Mol Biol Transl Sci; 2019; 164():119-188. PubMed ID: 31383404
[TBL] [Abstract][Full Text] [Related]
20. Review of squamous premalignant vulvar lesions.
van de Nieuwenhof HP; van der Avoort IA; de Hullu JA
Crit Rev Oncol Hematol; 2008 Nov; 68(2):131-56. PubMed ID: 18406622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
